blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3908583

EP3908583 - DOT1L DEGRADERS AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  15.10.2021
Database last updated on 21.05.2024
FormerThe international publication has been made
Status updated on  18.07.2020
Most recent event   Tooltip29.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
[2021/46]
Inventor(s)01 / ARMSTRONG, Scott
233 Rice Road
Wayland, MA 01778 / US
02 / QI, Jun
26 Pine Grove Avenue
Sharon, MA 02067 / US
[N/P]
Former [2021/46]01 / ARMSTRONG, Scott
Wayland, MA 01778 / US
02 / QI, Jun
Sharon, MA 02067 / US
Representative(s)Haseltine Lake Kempner LLP
Cheapside House
138 Cheapside
London EC2V 6BJ / GB
[2021/46]
Application number, filing date20739213.509.01.2020
[2021/46]
WO2020US12825
Priority number, dateUS201962790314P09.01.2019         Original published format: US 201962790314 P
[2021/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020146561
Date:16.07.2020
Language:EN
[2020/29]
Type: A1 Application with search report 
No.:EP3908583
Date:17.11.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 16.07.2020 takes the place of the publication of the European patent application.
[2021/46]
Search report(s)International search report - published on:US16.07.2020
(Supplementary) European search report - dispatched on:EP08.07.2022
ClassificationIPC:C07H19/167, A61P35/00
[2022/32]
CPC:
C07H19/167 (EP); C07H19/16 (US); A61P35/00 (EP);
A61P35/02 (US)
Former IPC [2021/46]C07D401/14, C07D471/04, C07D487/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/46]
TitleGerman:DOT1L-DEGRADER UND VERWENDUNGEN DAVON[2021/46]
English:DOT1L DEGRADERS AND USES THEREOF[2021/46]
French:AGENTS DE DÉGRADATION DE DOT1L ET UTILISATIONS ASSOCIÉES[2021/46]
Entry into regional phase27.06.2021National basic fee paid 
27.06.2021Search fee paid 
27.06.2021Designation fee(s) paid 
27.06.2021Examination fee paid 
Examination procedure27.06.2021Examination requested  [2021/46]
05.02.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.01.2022Renewal fee patent year 03
27.01.2023Renewal fee patent year 04
29.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2014153001  (EPIZYME INC [US]) [A] 1-15 * the whole document *;
 [AP]WO2020006157  (DANA FARBER CANCER INST INC [US]) [AP] 1-15* the whole document *
International search[Y]US2016106725  (RODEN RICHARD B [US], et al) [Y] 1-3, 34 * , entire document, especially: abstract; para [0007]; pg 26, Table 7, formula RA190F; para [0155]; para [0153]. *;
 [A]US2017232030  (KLAUS CHRISTINE [US], et al) [A] 1-3, 34* , entire document. *;
 [Y]  - KLAUS et al., "DOT1 L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells", J Pharmacol Exp Ther., (20140000), vol. 350, doi:10.1124/jpet.114.214577, pages 646 - 656, XP055292901 [Y] 1-3,34 * , entire document, especially: abstract, EPZ-5676. *

DOI:   http://dx.doi.org/10.1124/jpet.114.214577
 [A]  - PubChem, (20120709), Database accession no. 57345410, XP055724863 [A] 1-3, 34 * , pg 2, Fig. *
by applicantWO2014153001
 US2016058872
 US2016060269
 US2016106725
 US9694084
 US9913834
    - WILEN et al., Tetrahedron, (19770000), vol. 33, page 2725
    - WILEN, Tables of Resolving Agents and Optical Resolutions, Univ. of Notre Dame Press, (19720000), page 268
    - BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 501 - 502
    - BUNDGARD, H., Design of Prodrugs, Elsevier, (19850000), vol. 21-24, pages 7 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.